[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Gómez Sancha
F
F
Servicio de Urología, Hospital Universitario de La Princesa, Madrid.
Fernández Arjona
M
M
Peinado Ibarra
F
F
Fernández Borrell
A
A
Mínguez Martínez
R
R
Pereira Sanz
I
I
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use; D006801:Humans; D007217:Indoramin / Q000627:therapeutic use; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D013449:Sulfonamides; D010643:Phenoxybenzamine; D007217:Indoramin; C041226:Terazosin; C047638:alfuzosin; D000077409:Tamsulosin; D017292:Doxazosin; D011224:Prazosin